AR050693A1 - Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune. - Google Patents

Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.

Info

Publication number
AR050693A1
AR050693A1 ARP050103369A ARP050103369A AR050693A1 AR 050693 A1 AR050693 A1 AR 050693A1 AR P050103369 A ARP050103369 A AR P050103369A AR P050103369 A ARP050103369 A AR P050103369A AR 050693 A1 AR050693 A1 AR 050693A1
Authority
AR
Argentina
Prior art keywords
immune response
suppression
interleuquina
mutant
compositions containing
Prior art date
Application number
ARP050103369A
Other languages
English (en)
Original Assignee
Zheng Xin Xiao
Thomas Moll
Strom Terry B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zheng Xin Xiao, Thomas Moll, Strom Terry B filed Critical Zheng Xin Xiao
Publication of AR050693A1 publication Critical patent/AR050693A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Métodos de tratamiento de pacientes que han recibido, o programados para recibir, un transplante de corazon, de pulmon o cardio-pulmonar mediante la administracion a dichos pacientes de un agente que antagoniza la IL-15 o al receptor de IL-15 (IL- 15R). Reivindicacion 13: Uso de un polipéptido o de una molécula de ácido nucleico, caracterizado porque es para suprimir supresion de una respuesta inmune dependiente de IL-15, donde el polipéptido comprende la SEQ ID No.:6 y la molécula de ácido nucleico comprende una secuencia que codifica al polipéptido de la SEQ ID No.:6.
ARP050103369A 2004-08-11 2005-08-11 Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune. AR050693A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60104204P 2004-08-11 2004-08-11
US60047804P 2004-08-11 2004-08-11

Publications (1)

Publication Number Publication Date
AR050693A1 true AR050693A1 (es) 2006-11-15

Family

ID=35839987

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103371A AR050293A1 (es) 2004-08-11 2005-08-11 Polipeptidos de interleuquina-15 mutante
ARP050103369A AR050693A1 (es) 2004-08-11 2005-08-11 Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050103371A AR050293A1 (es) 2004-08-11 2005-08-11 Polipeptidos de interleuquina-15 mutante

Country Status (4)

Country Link
US (2) US20060057102A1 (es)
AR (2) AR050293A1 (es)
TW (2) TW200619227A (es)
WO (2) WO2006020849A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
US20060057102A1 (en) * 2004-08-11 2006-03-16 Zheng Xin X Mutant interleukin-15-containing compositions and suppression of an immune response
NZ581779A (en) 2005-05-17 2011-09-30 Univ Connecticut Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
BRPI0707106B1 (pt) 2006-01-13 2022-06-07 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Polinucleotídeo interleucina-15, vetor de expressão, e, composição farmacêutica
EP1921452A1 (en) * 2006-11-08 2008-05-14 Medizinische Hochschule Hannover Method for the diagnosis of leukemia
KR100888022B1 (ko) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US20110020269A1 (en) * 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
JP2010531878A (ja) 2007-06-27 2010-09-30 マリン ポリマー テクノロジーズ，インコーポレーテッド ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
US9155801B2 (en) 2009-05-28 2015-10-13 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
US8871191B2 (en) 2009-08-14 2014-10-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 preparations to treat lymphopenia
WO2015048149A1 (en) * 2013-09-24 2015-04-02 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
CN107001438A (zh) * 2014-10-14 2017-08-01 阿尔莫生物科技股份有限公司 白细胞介素‑15组合物及其用途
EP3350205A1 (en) * 2015-09-16 2018-07-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
BR112018012262A2 (pt) * 2015-12-21 2018-12-04 Armo Biosciences Inc composições de interleucina-15 e seus usos
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
CA3046387A1 (en) * 2016-12-21 2018-06-28 David Jose Simon LAINE Antibodies that specifically bind to human il-15 and uses thereof
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
AU2018328209A1 (en) 2017-09-05 2020-04-23 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
SG11202007728QA (en) * 2018-02-26 2020-09-29 Synthorx Inc Il-15 conjugates and uses thereof
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
JP2022533222A (ja) 2019-05-20 2022-07-21 サイチューン ファーマ 癌又は感染性疾患を処置するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト投薬レジメン
JP2023512452A (ja) * 2020-01-13 2023-03-27 ンカルタ・インコーポレイテッド Ｂｃｍａ指向性細胞免疫療法組成物および方法
WO2022090202A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
WO2022090203A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
EP4359429A1 (en) 2021-06-23 2024-05-01 Cytune Pharma Interleukin 15 variants
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
CN113956346B (zh) * 2021-10-26 2024-03-01 西安龙腾景云生物科技有限公司 一种重组白介素-15变体
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
DE69733610T2 (de) * 1996-04-26 2006-05-11 Beth Israel Deaconess Medical Center, Inc., Boston Interleukin-15 antagonisten
US6451308B1 (en) * 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
US20060057102A1 (en) * 2004-08-11 2006-03-16 Zheng Xin X Mutant interleukin-15-containing compositions and suppression of an immune response
WO2007018564A2 (en) * 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of b cell proliferation by il-15

Also Published As

Publication number Publication date
WO2006017853A2 (en) 2006-02-16
WO2006020849A2 (en) 2006-02-23
TW200613552A (en) 2006-05-01
WO2006020849A3 (en) 2006-10-05
US20060057102A1 (en) 2006-03-16
TW200619227A (en) 2006-06-16
AR050293A1 (es) 2006-10-11
WO2006017853A3 (en) 2007-01-04
US20060057680A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
AR050693A1 (es) Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.
HUP0303879A2 (hu) Zsíralkohol-etoxilátok alkalmazása penetrációt elősegítő szerként
HK1084404A1 (en) Muteins of tear lipocalin
NZ562998A (en) Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
HK1107030A1 (en) Oligopeptides for reducing elevated blood urea concentration
CA2638826C (en) A mycobacterium tuberculosis fusion protein and uses thereof
MX2007003078A (es) Compuestos de imidazoquinolina.
GB9818627D0 (en) Improvements in dva vaccination
ATE429445T1 (de) Verfahren zur herstellung von carboxy-terminal amidierten peptiden
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
HUP0302026A2 (hu) Növekedési hormon szekrécióját fokozó triptofánszármazékok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
EA200702254A1 (ru) Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант
DE59507920D1 (de) NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
JP2019534307A (ja) 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法
Mair Mummies of the Tarim basin.
UA101140C2 (ru) Комбинация рекомбинантной микобактерии и биологически активного агента как вакцины
MX2009012676A (es) Neuraminidasa neumococica no toxica y sus usos.
HUP0105070A2 (hu) Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
MXPA02009781A (es) Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
ES2176334T3 (es) El uso de gabapentin en el tratamiento de la ansiedad y el panico.
ATE435237T1 (de) Durch homogene bluttransfusion induziertes protein und für dieses kodierende dna
GB0409559D0 (en) Polypeptide
JP2007517775A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure